Drugs / ABT-354
last change Nov 2013 re-read 3 minutes ago

ABT-354

Developed for
Alzheimer disease
Investigated by
AbbVie

Trials 1

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01908010 Jul → Nov 2013 Alzheimer disease AbbVie Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ABT-354 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01908010 ↗